## Alexander Judkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6817902/publications.pdf

Version: 2024-02-01

44 papers 2,465 citations

394421 19 h-index 377865 34 g-index

45 all docs

45 docs citations

45 times ranked

5080 citing authors

#	Article	IF	CITATIONS
1	A Practical Approach to the Evaluation and Diagnosis of Pediatric CNS Tumors. Pediatric and Developmental Pathology, 2022, 25, 6-9.	1.0	1
2	Evaluation and Diagnosis of Central Nervous System Embryonal Tumors (Non-Medulloblastoma). Pediatric and Developmental Pathology, 2022, 25, 34-45.	1.0	5
3	Intraoperative Diagnosis for Pediatric Brain Tumors. Pediatric and Developmental Pathology, 2022, 25, 10-22.	1.0	3
4	High Prevalence of SARS-CoV-2 Genetic Variation and D614G Mutation in Pediatric Patients With COVID-19. Open Forum Infectious Diseases, 2021, 8, ofaa551.	0.9	26
5	Rapidly emerging SARS-CoV-2 B.1.1.7 sub-lineage in the United States of America with spike protein D178H and membrane protein V70L mutations. Emerging Microbes and Infections, 2021, 10, 1293-1299.	6.5	18
6	Emerging variants of concern in SARS-CoV-2 membrane protein: a highly conserved target with potential pathological and therapeutic implications. Emerging Microbes and Infections, 2021, 10, 885-893.	6.5	44
7	Histopathological patterns in atypical teratoid/rhabdoid tumors are related to molecular subgroup. Brain Pathology, 2021, 31, e12967.	4.1	16
8	Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series. EBioMedicine, 2021, 67, 103355.	6.1	128
9	Autopsy findings of previously described case of diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. Acta Neuropathologica Communications, 2021, 9, 113.	5.2	1
10	Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas. Science Translational Medicine, 2021, 13, eabf7860.	12.4	18
11	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Science Translational Medicine, 2021, 13, eabc0497.	12.4	29
12	Whose Data, Whose Risk? Omics Privacy Concerns Should be Defined by Individuals, not Researchers. American Journal of Bioethics, 2021, 21, 67-70.	0.9	2
13	SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. Neuro-Oncology, 2020, 22, 785-796.	1.2	18
14	Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. Cancer Cell, 2020, 38, 334-349.e9.	16.8	87
15	Reply to S.A. Upadhyaya. Journal of Clinical Oncology, 2020, 38, 3353-3354.	1.6	4
16	Comprehensive Genome Analysis of 6,000 USA SARS-CoV-2 Isolates Reveals Haplotype Signatures and Localized Transmission Patterns by State and by Country. Frontiers in Microbiology, 2020, 11, 573430.	3.5	17
17	<scp>SMARCB1</scp> loss induces druggable cyclin <scp>D1</scp> deficiency via upregulation of <scp><i>MIR17HG</i></scp> in atypical teratoid rhabdoid tumors. Journal of Pathology, 2020, 252, 77-87.	4.5	11
18	Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. Acta Neuropathologica Communications, 2020, 8, 37.	5.2	20

#	Article	IF	CITATIONS
19	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro-Oncology, 2020, 22, 944-954.	1.2	25
20	Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children's Oncology Group Trial ACNS0333. Journal of Clinical Oncology, 2020, 38, 1175-1185.	1.6	102
21	CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nature Communications, 2019, 10, 558.	12.8	76
22	SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nature Communications, 2019, 10, 557.	12.8	125
23	Pediatric Atypical Teratoid/Rhabdoid Tumors of the Brain: Identification of Metabolic Subgroups Using In Vivo <sup>1</sup> H-MR Spectroscopy. American Journal of Neuroradiology, 2019, 40, 872-877.	2.4	6
24	Fitting the epigenome into the picture: methylation classification for paediatric brain tumours. Neuropathology and Applied Neurobiology, 2018, 44, 543-547.	3.2	0
25	Transmission of a TP53 germline mutation from unaffected male carrier associated with pediatric glioblastoma in his child and gestational choriocarcinoma in his female partner. Journal of Physical Education and Sports Management, 2018, 4, a002576.	1.2	8
26	ATRT-22. SWI/SNF COMPLEX HETEROGENEITY RELATES WITH POLYPHENOTYPIC DIFFERENTIATION AND THE IMMUNE MICRO ENVIRONMENT IN RHABDOID TUMORS. Neuro-Oncology, 2018, 20, i32-i32.	1.2	0
27	OncoKids. Journal of Molecular Diagnostics, 2018, 20, 765-776.	2.8	58
28	Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development. Nature Communications, 2017, 8, 300.	12.8	70
29	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathologica, 2017, 134, 705-714.	7.7	168
30	AT-23ENCOURAGING SURVIVAL OF PEDIATRIC CENTRAL NERVOUS SYSTEM (CNS) ATYPICAL TERATOID AND RHABDOID TUMOR (AT/RT) TREATED AS PER CHILDREN'S ONCOLOGY GROUP ACNS0333 STUDY: A SINGLE-INSTITUTION EXPERIENCE. Neuro-Oncology, 2016, 18, iii6.3-iii6.	1.2	0
31	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
32	AT-21INTEGRATED (EPI)GENOMIC ANALYSES IDENTIFY SUB-GROUP SPECIFIC THERAPEUTIC TARGETS IN CNS RHABDOID TUMORS. Neuro-Oncology, 2016, 18, iii6.1-iii6.	1.2	0
33	A Rapid and Sensitive Next-Generation Sequencing Method to Detect RB1 Mutations Improves Care for Retinoblastoma Patients and Their Families. Journal of Molecular Diagnostics, 2016, 18, 480-493.	2.8	26
34	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Science Translational Medicine, 2016, 8, 366ra161.	12.4	144
35	Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. Neuro-Oncology, 2016, 18, 126-131.	1.2	69
36	Hypoxia Induces Production of L-2-Hydroxyglutarate. Cell Metabolism, 2015, 22, 304-311.	16.2	374

#	Article	IF	CITATIONS
37	MB-34 * MOLECULAR SUBGROUPS OF MEDULLOBLASTOMA IDENTIFICATION USING NON-INVASIVE MAGNETIC RESONANCE SPECTROSCOPY. Neuro-Oncology, 2015, 17, iii27-iii27.	1.2	0
38	PM-02 * CONDITIONAL INACTIVATION OF SMARCB1 IN PO PERMISSIVE MOUSE CELLS GENERATES RHABDOID TUMORS IN THE PERIPHERAL NERVOUS SYSTEM AND IN THE BRAIN. Neuro-Oncology, 2015, 17, iii31-iii31.	1.2	0
39	Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas. Clinical Cancer Research, 2015, 21, 1457-1465.	7.0	92
40	Ganglioglioma of the Spinal Cord. Journal of Clinical Imaging Science, 2015, 5, 53.	1.1	16
41	Pathology and diagnosis of SMARCB1-deficient tumors. Cancer Genetics, 2014, 207, 358-364.	0.4	81
42	Asparagine Plays a Critical Role in Regulating Cellular Adaptation to Glutamine Depletion. Molecular Cell, 2014, 56, 205-218.	9.7	347
43	A texture-based classifier to discriminate anaplastic from non-anaplastic medulloblastoma., 2011,,.		4
44	Segmentation of nodular medulloblastoma using Random Walker and Hierarchical Normalized Cuts. , 2011, , .		6